Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Pharmaceuticals Holding Co. is conducting a Phase II clinical study titled ‘A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Safety and Efficacy of LT3001 in Subjects With Acute Ischemic Stroke (AIS).’ The study aims to assess the safety and efficacy of LT3001, a drug intended to treat acute ischemic stroke, a condition that occurs when blood flow to the brain is obstructed.
The study tests LT3001, administered via intravenous infusion in both high and low doses, against a placebo. This intervention aims to improve outcomes for patients suffering from acute ischemic stroke by potentially reducing the severity of the condition.
This interventional study employs a randomized, parallel assignment model with double masking, meaning both participants and investigators are unaware of the treatment allocation. The primary purpose of the study is treatment-focused, aiming to determine the effectiveness of LT3001 in treating acute ischemic stroke.
The study began on January 9, 2023, with primary completion expected by April 10, 2025. These dates are crucial as they mark the phases of data collection and analysis, which will influence subsequent regulatory decisions and market availability.
The outcome of this study could significantly impact Shanghai Pharmaceuticals’ stock performance, as positive results may enhance investor confidence and market position. The pharmaceutical industry is highly competitive, and advancements in stroke treatment could offer a competitive edge.
The study is currently recruiting, with further updates and details accessible on the ClinicalTrials portal.